Navigation Links
Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
Date:11/28/2007

Acquisition of Remainder of NexGen Diagnostics Captures Promising

Intellectual Property

FULLERTON, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer of products that simplify and automate complex biomedical testing announced today that it has entered into an agreement to acquire the remaining 80.1 percent of NexGen Diagnostics LLC, a spin out of Lumigen, Inc., effected prior to Beckman Coulter's acquisition of Lumigen in 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

Since NexGen's assets consist of intellectual property unrelated to current products, Beckman Coulter expects to take a charge of approximately $36 million for in-process R&D when the acquisition closes in the fourth quarter of 2007. The technologies have the potential to revolutionize high sensitivity testing, including immunoassay and nucleic acid, due to their inherently superior speed and simplicity.

Richard Creager, corporate vice president of Beckman Coulter's Immunoassay Business Center, said, "We are very enthusiastic about the potential that these proprietary technologies have to improve patient health and reduce the cost of care. If fully realized, they will simplify and automate certain types of immunodiagnostic and nucleic acid testing in remarkable ways, dramatically enhancing the performance of assays and accelerating turn-around time of test results."

The dramatic improvement in turn-around time is a result of a proprietary non-separation immunoassay technology which eliminates time-consuming steps while maintaining the exquisite sensitivity of the assays. Consistent with the company's commitment to develop a sample to result molecular testing system for clinical diagnostics, the acquired nucleic acid technology will allow rapid isolation of DNA or RNA from a patient sample without a separate step or reagent.

About Beckman Coulter, Inc.

Based in Fullerton, California, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue consisting of supplies, test kits, service and operating-type lease payments represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit http://www.beckmancoulter.com.

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the contribution of the acquired technology to Beckman Coulter's R&D and product development capability. These statements are based on current expectations and assumptions. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond Beckman Coulter's control. Factors that affect the development of new technologies are described in Beckman Coulter's 10-K report filed with the SEC on February 26, 2007 and its 10-Q reports and other SEC filings.

Contacts:

Mary Luthy, Beckman Coulter Robert Raynor, Beckman Coulter

Corporate Communications Investor Relations

(714) 773-7964 (714) 773-7620


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
10. Neogen Acquires Kane Enterprises
11. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
Breaking Biology Technology:
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):